Phaseline

Companies › SOFIE

SOFIE: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 3; Oncology; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
[18F]FAPI-74
FAP-targeting radioactive diagnostic agent for PET imaging
FAPPhase 3Esophageal Cancer; Pancreatic Ductal Adenocarcinoma (PDAC)Aug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07217704[18F]FAPI-74Phase 3Esophageal CancerOncologyAug 2027
NCT07217717[18F]FAPI-74Phase 3Pancreatic Ductal Adenocarcinoma (PDAC)OncologyDec 2027

Targets

FAP (1)

Companies with the same targets

Chengdu New Radiomedicine Technology Avacta Life Sciences Blue Earth Diagnostics Novartis Ratio Therapeutics Beijing Biotech Philogen BioInvent International Lantheus Medical Imaging Perspective Therapeutics

Companies built like this

Blue Earth Diagnostics Chengdu New Radiomedicine Technology LaNova Medicines Zhejiang Quetzal Therapeutics Beijing Pearl Biotechnology Limited Liability Company

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.